Metabolomic Technologies

About:

Metabolomic Technologies develops patented, metabolomic-based, diagnostic tests to detect adenomatous polyps and colorectal cancer (CRC).

Website: https://www.mtidx.com

Twitter/X: metabolomictech

Top Investors: Alberta Innovates, VA Angels, Tribune Capital, Advanced Technology Centre

Description:

Metabolomic Technologies Inc. (MTI) is a spin-off company from the University of Alberta. The company was formed from a research program facilitated by Drs. Haili Wang and Richard Fedorak, who were interested in using the new science of metabolomics to explore how colorectal cancer and adenomatous (precancerous) polyps affected cellular metabolism. At MTI, they are committed to developing advanced metabolomic-based diagnostic tests for the management of chronic diseases or ‘high value’ diagnostics. Their initial focus is on developing highly novel, patented, metabolomic-based, diagnostic tests to detect adenomatous polyps and colorectal cancer (CRC). CRC is a leading cause of death in North America, but is curable if identified through early screening processes. However, current fecal-based screening methodologies are suboptimal due to a lack of sensitivity and acceptability. Their flagship product, PolypDx™, a spot urine diagnostic test, innovatively offers a significantly higher sensitivity in detecting adenomatous polyps and thus significantly advances the prevention of CRC.